Long chain omega-3 fatty acids and their oxidized metabolites are associated with reduced prostate tumor growth.

[1]  M. V. Van Elswyk,et al.  A Scoping Review of Interactions between Omega-3 Long-Chain Polyunsaturated Fatty Acids and Genetic Variation in Relation to Cancer Risk , 2020, Nutrients.

[2]  David S. Wishart,et al.  Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics Data Analysis , 2019, Current protocols in bioinformatics.

[3]  K. Robitaille,et al.  Omega-3 Fatty Acids Survey in Men under Active Surveillance for Prostate Cancer: from Intake to Prostate Tissue Level , 2019, Nutrients.

[4]  A. Bergeron,et al.  Omega‐3 fatty acids decrease prostate cancer progression associated with an anti‐tumor immune response in eugonadal and castrated mice , 2018, The Prostate.

[5]  W. Fraser,et al.  F2-isoprostanes and fatty acids profile in early pregnancy complicated by pre-existing diabetes. , 2018, Prostaglandins, leukotrienes, and essential fatty acids.

[6]  Sui Huang,et al.  Resolvins suppress tumor growth and enhance cancer therapy , 2018, The Journal of experimental medicine.

[7]  P. Julien,et al.  Modulation of the biomarkers of inflammation and oxidative stress by ruminant trans fatty acids and dairy proteins in vascular endothelial cells (HUVEC). , 2017, Prostaglandins, leukotrienes, and essential fatty acids.

[8]  M. Giera,et al.  Isoprostanes, neuroprostanes and phytoprostanes: An overview of 25years of research in chemistry and biology. , 2017, Progress in lipid research.

[9]  P. Julien,et al.  Trans Fatty Acids Suppress TNF-α-Induced Inflammatory Gene Expression in Endothelial (HUVEC) and Hepatocellular Carcinoma (HepG2) Cells , 2017, Lipids.

[10]  T. Wakai,et al.  Resolvins and omega three polyunsaturated fatty acids: Clinical implications in inflammatory diseases and cancer. , 2016, World journal of clinical cases.

[11]  J. Galano,et al.  Polymeric nanocapsules prevent oxidation of core-loaded molecules: evidence based on the effects of docosahexaenoic acid and neuroprostane on breast cancer cells proliferation , 2015, Journal of Experimental & Clinical Cancer Research.

[12]  Erik Sahai,et al.  Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity , 2015, Cell.

[13]  C. Serhan,et al.  Human Milk Proresolving Mediators Stimulate Resolution of Acute Inflammation , 2015, Mucosal Immunology.

[14]  J. Galano,et al.  Nonenzymatic lipid mediators, neuroprostanes, exert the antiarrhythmic properties of docosahexaenoic acid. , 2015, Free radical biology & medicine.

[15]  W. Fraser,et al.  Plasma F2-isoprostane class VI isomers at 12-18 weeks of pregnancy are associated with later occurrence of preeclampsia. , 2015, Free radical biology & medicine.

[16]  J. Galano,et al.  Total syntheses and in vivo quantitation of novel neurofuran and dihomo-isofuran derived from docosahexaenoic acid and adrenic acid. , 2015, Chemistry.

[17]  B. Levy,et al.  Lipid mediators in the resolution of inflammation. , 2015, Cold Spring Harbor perspectives in biology.

[18]  G. Fan,et al.  Roles of resolvins in the resolution of acute inflammation , 2015, Cell biology international.

[19]  C. Serhan,et al.  Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. , 2014, American journal of physiology. Cell physiology.

[20]  J. Galano,et al.  Oxygenated metabolites of n-3 polyunsaturated fatty acids as potential oxidative stress biomarkers: total synthesis of 8-F3t-IsoP, 10-F4t-NeuroP and [D4]-10-F4t-NeuroP. , 2014, Chemistry.

[21]  P. Julien,et al.  Prostatic and Dietary Omega-3 Fatty Acids and Prostate Cancer Progression during Active Surveillance , 2014, Cancer Prevention Research.

[22]  I. Thompson,et al.  Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. , 2014, Journal of the National Cancer Institute.

[23]  J. Schwarze,et al.  The role of pro-resolution lipid mediators in infectious disease , 2014, Immunology.

[24]  A. Bahonar,et al.  The Effect of Omega-3 Supplements on Antioxidant Capacity in Patients with Type 2 Diabetes , 2013, International journal of preventive medicine.

[25]  D. Rosenberg,et al.  Multifaceted roles of PGE2 in inflammation and cancer , 2013, Seminars in Immunopathology.

[26]  M. Bryś,et al.  Relationship of urinary isoprostanes to prostate cancer occurence , 2012, Molecular and Cellular Biochemistry.

[27]  K. Kuroiwa,et al.  Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer. , 2012, The Journal of urology.

[28]  C. Galet,et al.  Phase II Prospective Randomized Trial of a Low-Fat Diet with Fish Oil Supplementation in Men Undergoing Radical Prostatectomy , 2011, Cancer Prevention Research.

[29]  J. Morrow,et al.  Oxidative stress measured by urine F2-isoprostane level is associated with prostate cancer. , 2011, The Journal of urology.

[30]  I. Thompson,et al.  Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. , 2011, American journal of epidemiology.

[31]  R. DuBois,et al.  Eicosanoids and cancer , 2010, Nature Reviews Cancer.

[32]  J. Witte,et al.  Dietary Omega-3 Fatty Acids, Cyclooxygenase-2 Genetic Variation, and Aggressive Prostate Cancer Risk , 2009, Clinical Cancer Research.

[33]  V. Castronovo,et al.  Activation of the thromboxane A2 pathway in human prostate cancer correlates with tumor Gleason score and pathologic stage. , 2006, European urology.

[34]  J. Lewin,et al.  Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. , 2004, Cancer research.

[35]  G. FitzGerald,et al.  F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases. , 2004, Chemistry and physics of lipids.

[36]  N. Behrendt,et al.  Inuit are protected against prostate cancer. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[37]  A. Kafatos,et al.  Prostate cancer vs hyperplasia: relationships with prostatic and adipose tissue fatty acid composition. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[38]  M. Kesavulu,et al.  Effect of omega-3 fatty acids on lipid peroxidation and antioxidant enzyme status in type 2 diabetic patients. , 2002, Diabetes & metabolism.

[39]  B. Koller,et al.  Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. , 2001, The Journal of clinical investigation.

[40]  J. Morrow,et al.  Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. , 2000, Free radical biology & medicine.

[41]  F. Visioli,et al.  Long-chain omega 3 fatty acids: molecular bases of potential antioxidant actions. , 2014, Prostaglandins, leukotrienes, and essential fatty acids.

[42]  M. Vohl,et al.  Transcriptomic and metabolomic signatures of an n-3 polyunsaturated fatty acids supplementation in a normolipidemic/normocholesterolemic Caucasian population. , 2013, The Journal of nutritional biochemistry.

[43]  M. Tjepkema,et al.  Cancer patterns in Inuit Nunangat: 1998-2007. , 2012, International journal of circumpolar health.

[44]  G. Maskarinec,et al.  The effect of migration on cancer incidence among Japanese in Hawaii. , 2004, Ethnicity & disease.